<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1383</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2004</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<volume>2</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Preparation of [64Cu] Pyruvaldehyde-bis (N4-methylthiosemicarbazone) complex as a PET and/or therapeutic radiopharmaceutical</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Copper-64 (T&lt;sub&gt;1/2&lt;/sub&gt;=12.7 h) is an important radionuclide used both in PET imaging and therapy. [&lt;sup&gt;64&lt;/sup&gt;Cu]-pyruvaldehyde-&lt;i&gt;bis &lt;/i&gt;(N&lt;sup&gt;4&lt;/sup&gt;-methylthiosemicarbazone) ([&lt;sup&gt;64&lt;/sup&gt;Cu]-PTSM) is one of the most famous copper radiopharmaceuticals with unique specifications (suitable half life, &lt;br&gt;stability, etc.). The wide range of &lt;sup&gt;64&lt;/sup&gt;Cu applications arouse great interest for its production. &lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and Methods: &lt;/strong&gt;Cu-64 was produced &lt;i&gt;via&lt;/i&gt; the &lt;sup&gt;68&lt;/sup&gt;Zn (p, α n) &lt;sup&gt;64&lt;/sup&gt;Cu nuclear reaction and isolated from the irradiated target by a two-step chemical method. [&lt;sup&gt;64&lt;/sup&gt;Cu]-PTSM was prepared using in-house made PTSM ligand and [&lt;sup&gt;64&lt;/sup&gt;Cu] cuprous acetate. The complex formation parameter s (time, temperature, concentration and elution methods) were determined carefully. &lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Copper-64 was prepared in chloride form (≈200 mCi, &gt;95% chemical yield at 180 μA for 1.1 h irradiation, radionuclidic purity &gt;96%, copper-67 as impurity). The solution of &lt;sup&gt;64&lt;/sup&gt;Cu-PTSM was prepared in &gt;80% radiochemical yield and more than 98% radiochemical purity. Quality controls and stability tests were performed for the final solution. &lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;[&lt;sup&gt;64&lt;/sup&gt;Cu]-PTSM was prepared at the radiopharmaceutical scales with high quality and potential to be used in therapeutic/imaging centers. &lt;i&gt;Iran &lt;/i&gt;&lt;i&gt;. J. Radiat. Res., 2004 2 (3): 107-115 &lt;/i&gt;&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>,hypoxia imaging, cyclotron,targeted therapy, PTSM,Copper-64,PET</keyword>
	<start_page>107</start_page>
	<end_page>115</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-66&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>A.R. Jalilian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ajalilian@nrcam.org</email>
	<code>79003194753284600162</code>
	<orcid>79003194753284600162</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>P. Rowshanfarzad</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600163</code>
	<orcid>79003194753284600163</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>J. Moafian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600164</code>
	<orcid>79003194753284600164</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>M. Kamali-dehghan</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600165</code>
	<orcid>79003194753284600165</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name></first_name>
	<middle_name></middle_name>
	<last_name>M. Mirzaii</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>79003194753284600166</code>
	<orcid>79003194753284600166</orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
